Pharex and AB-BIOTICS join efforts to launch an innovative probiotic for cholesterol in the Philippines

2 December 2021 – 2 min read

Hyperlipidemia is one of the main health concerns in the Philippines. According to latest data, almost half of Filipinos aged 20 and over have borderline high cholesterol, leading to ischaemic heart disease as the first cause of death among men and women in the country (14.5% of total mortalities).

To offer a preventive, natural solution to Filipinos in risk, Pharex in collaboration with AB-BIOTICS has recently launched Biome Lipidec.

Pharex Health Corporation is a Philippine pharmaceutical company, an affiliate of Ritemed Inc, which is part of United Laboratories, Inc (Unilab). Pharex is short for Pharmaceutical Excellence, believing strongly that all its products are of superior quality. Biome Lipidec is the first probiotic solution of their portfolio, bringing to the market an innovative and natural therapy for hyperlipidemia.

Biome Lipidec contains a mix of three L. plantarum strains (AB-LIFE):

L. plantarum KABP™ 011
L. plantarum KABP™ 012
L. plantarum KABP™ 013

AB-LIFE has been highly studied for hyperlipidemia, showing a high percentage of reduction in LDL-cholesterol, total cholesterol and triglycerides in blood. 

Biome Lipidec value proposition focuses on the product’s mechanism of action and clinically-proven effects:

 “Your probiotic ally for cholesterol management.” Lipidec is a probiotic supplement that inhibits the re-absorption of bile salts and facilitates their excretion through the intestine. In order to produce new bile salts, the liver needs to extract more cholesterol from blood and as a result, blood cholesterol levels are reduced.

Although other natural options are present in the market, Biome Lipidec is one of the first probiotics in the Philippines indicated for high blood lipids, seen as an innovative product between healthcare professionals.

Pharex has developed a strong communication campaign in order to increase general awareness of probiotics for cholesterol in the country, in order to spread the therapeutic benefits of Lipidec, and impact as many Filipinos as possible.

Authors: Claudia Prat (Human Biologist)